Dr. Duska on the Utility of the Fagotti Score in Advanced Ovarian Cancer

Video

In Partnership With:

Linda R. Duska, MD, professor of obstetrics and gynecology and gynecologic oncologist at the University of Virginia, explains whether the Fagotti score provides an accurate assessment of whether a patient with newly diagnosed, advanced ovarian cancer can achieve a complete resection in surgery.

Linda R. Duska, MD, professor of obstetrics and gynecology and gynecologic oncologist at the University of Virginia, explains whether the Fagotti score provides an accurate assessment of whether a patient with newly diagnosed, advanced ovarian cancer can achieve a complete resection in surgery.

The Fagotti score can be useful in determining whether a patient with newly diagnosed, advanced ovarian cancer can undergo optimal debulking surgery in the hands of an experienced surgeon, explains Duska. However, it is not the sole way to assess resectability. A small laparotomy could be performed instead, in addition to performing imaging, a CT scan, a PET scan, or an MRI, says Duska.

Ultimately, resectability should be assessed by a trained gynecologic oncologist. Having a gynecologic oncologist involved in the care of women with advanced disease from the onset of treatment is important, says Duska. However, that is not always possible, especially in community practices where general surgeons or gynecologists are more likely to perform the surgery. When that happens, the patient’s likelihood of receiving an appropriate surgery decreases, concludes Duska.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS